Literature DB >> 28710033

Glutathione S-transferase (GSTM1, GSTT1) polymorphisms and JOAG susceptibility: A case control study and meta-analysis in glaucoma.

Manzoor Ahmad Malik1, Viney Gupta2, Swati Shukla3, Jasbir Kaur4.   

Abstract

PURPOSE: Glutathione S transferase (GST) polymorphisms have been considered risk factors for the development of glaucoma. The aim of the present study was to investigate the association of glutathione S-transferase GSTT1 and GSTM1 genotypes with juvenile open-angle glaucoma (JOAG) in Indian patients.
METHODS: A case-control study was performed to investigate the associations of GSTM1 and GSTT1 in juvenile open-angle glaucoma. The genotype of GSTM1 and GSTT1 were determined in 73 juvenile open-angle glaucoma patients, and 70 controls matched by age and sex by polymerase chain reaction method. We also performed a meta-analysis of sixteen published studies on GSTM1 and GSTT1 and evaluated the association between the GSTM1 and GSTT1 polymorphisms and glaucoma (JOAG & POAG). Published literature from PubMed and other databases were retrieved. All studies evaluating the association between GSTM1 and GSTT1 polymorphisms and glaucoma (JOAG & POAG) risk were included. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random- or fixed-effects model.
RESULTS: In the present study, we observed there is no association of GSTM1 (OR=0.680; 95% CI=0.323-1.433; p=0.311) or GSTT1 (OR=0.698; 95% CI=0.307-1.586; p=0.391) with JOAG. In the present meta-analysis, significantly increased glaucoma (JOAG & POAG) risk was found among subjects carrying GSTM1 null genotype (OR=1.177; 95% CI=1.028-1.348; p=0.018) but not among subjects carrying GSTT1 deletion genotype (OR=1.186; 95% CI=0.992-1.417; p=0.061).
CONCLUSIONS: The present case-control study found that GSTM1 and GSTT1 polymorphism are not associated with JOAG risk in North Indian population. The present meta-analysis suggested that there might be a significant association of GSTM1 null genotype with glaucoma (JOAG & POAG) risk. To the best of our knowledge, this is the first study in the world to investigate role of GSTM1 and GSTT1 polymorphisms with JOAG susceptibility. Given the limited sample size, the associations between GST polymorphism and glaucoma risk needs further investigation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GSTM1/GSTT1; Gene polymorphisms; Glaucoma; JOAG; Meta-analysis; PCR

Mesh:

Substances:

Year:  2017        PMID: 28710033     DOI: 10.1016/j.gene.2017.07.028

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

Review 1.  Juvenile-onset open-angle glaucoma - A clinical and genetic update.

Authors:  Harathy Selvan; Shikha Gupta; Janey L Wiggs; Viney Gupta
Journal:  Surv Ophthalmol       Date:  2021-09-16       Impact factor: 6.197

2.  A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility.

Authors:  Zhiqing Zhong; Hongyan Li; Hongzhen Zhong; Tianbiao Zhou; Weiji Xie; Zhijun Lin
Journal:  BMC Med Genet       Date:  2018-06-08       Impact factor: 2.103

3.  Glutathione S-transferase gene polymorphisms and risk of nasal or colorectal polyposis.

Authors:  Yonglan Zhang; Haichao Zhang; Peng Lin; Guimin Zhang
Journal:  Biosci Rep       Date:  2019-01-25       Impact factor: 3.840

4.  Genetic variants of glutathione S-transferase and the risk of acute myeloid leukemia in a Saudi population.

Authors:  Abdullah Farasani
Journal:  Saudi J Biol Sci       Date:  2018-12-21       Impact factor: 4.219

5.  Indistinguishable gene expression between healthy eyes and eyes with unilateral exfoliative glaucoma.

Authors:  Marcelo Ayala; Filip Cuklev
Journal:  Clin Ophthalmol       Date:  2018-07-17

6.  Association Between Glutathione S-Transferase (GST) Polymorphisms and Schizophrenia in a Chinese Han Population.

Authors:  Ci Yan; Li Duan; Chunfeng Fu; Chunsheng Tian; Bihui Zhang; Xiaojun Shao; Gang Zhu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-18       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.